Mersana Therapeutics, Inc. (MRSN)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | 3,056 | 2,754 | 12,598 | 2,293 |
| Restructuring expense | 3,940 | - | - | - |
| Research and development | 16,218 | 18,341 | 14,803 | 17,245 |
| General and administrative | 7,415 | 8,925 | 9,864 | 10,503 |
| Total operating expenses | 27,573 | 27,266 | 24,667 | 27,748 |
| Interest income | 895 | 1,164 | 1,972 | 2,170 |
| Interest expense | 674 | 775 | 986 | 983 |
| Total other income, net | 221 | 389 | 986 | 1,187 |
| Loss before income taxes | - | - | -11,083 | - |
| Income tax expense | - | - | 418 | - |
| Net loss | -24,296 | -24,123 | -11,501 | -24,268 |
| Unrealized (loss) gain on marketable securities, net of tax | - | -10 | 96 | 19 |
| Comprehensive loss | -24,296 | -24,133 | -11,405 | -24,249 |
| Net loss per share attributable to common stockholders basic (in dollars per share) | -4.87 | -0.19 | -0.09 | -0.2 |
| Net loss per share attributable to common stockholders diluted (in dollars per share) | -4.87 | -0.19 | -0.09 | -0.2 |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders basic (in shares) | 4,986,784 | 124,466,113 | 122,721,918 | 122,440,124 |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders diluted (in shares) | 4,986,784 | 124,466,113 | 122,721,918 | 122,440,124 |